2023-03-16 10:27:20 ET
- Comera Life Sciences press release ( NASDAQ: CMRA ): Q4 GAAP EPS of -$0.18.
- Revenue of $0.15M (+114.3% Y/Y).
-
R&D expenses totaled $489 thousand for the three months ended December 31, 2022, compared to $490 thousand for the same period in 2021.
-
General and administrative expenses totaled $2.7 million for the three months ended December 31, 2022, compared to $1.6 million for the same period in 2021
-
Comera had $2.0 million in cash, cash equivalents, and restricted cash at December 31, 2022.
For further details see:
Comera Life Sciences GAAP EPS of -$0.18, revenue of $0.15M